全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Safety and Efficacy of Fingolimod in Treatment-Na ve Multiple Sclerosis Patients

DOI: 10.4137/JCNSD.S5120

Full-Text   Cite this paper   Add to My Lib

Abstract:

Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this is the first oral disease-modifying therapy, has lead to considerable enthusiasm amongst physicians and patients. However, fingolimod is associated with rare but serious adverse events. In addition, unlike conventional disease-modifying therapies, cardiopulmonary, ophthalmological and dermatological safety monitoring unfamiliar to both neurologists and patients is required before and during treatment. This paper will discuss these issues from the perspective of using fingolimod as a first-line disease-modifying therapy in treatment-na ve relapsing-remitting multiple sclerosis patients.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133